Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Illumina, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SEASONED HEALTHCARE CFO WITH SENIOR EXPERIENCE IN CAPITAL MARKETS AND FINANCIAL OPERATIONS ACROSS PRIVATE AND PUBLICLY TRADED COMPANIES TO LEAD BIOSTEM'S FINANCIAL TEAM POMPANO BEACH, FL, AUGUST 14, 2025  PRISM MEDIAWIRE  BIOSTEM TECHNOLOGIES, INC.

BIOSTEM TECHNOLOGIES APPOINTS BRANDON POE AS CHIEF FINANCIAL OFFICER

REVENUE OF $1.06 BILLION FOR Q2 2025, DOWN 3% FROM Q2 2024 ON BOTH A REPORTED AND CONSTANT CURRENCY BASIS GAAP OPERATING MARGIN OF 20.2% AND NON-GAAP OPERATING MARGIN OF 23.8% FOR Q2 2025 GAAP DILUTED EPS OF $1.49 AND NON-GAAP DILUTED EPS OF $1.19 FOR Q2 2025 CASH PROVIDED BY OPERATIONS OF $234 MILLION AND FREE CASH FLOW OF $204 MILLION FOR Q2 2025 FOR FISCAL YEAR 2025, WE NOW EXPECT: TOTAL COMPANY CONSTANT CURRENCY REVENUE DECLINE IN THE RANGE OF (2.5%) TO (0.5%), UP FROM (3%) TO (1%) PREVIOUSLY NON-GAAP OPERATING MARGIN OF APPROXIMATELY 22% - 22.5%, UP FROM 21.5% - 22.0% PREVIOUSLY NON-GAAP DILUTED EPS IN THE RANGE OF $4.45 - $4.55, AN INCREASE FROM OUR MAY GUIDANCE OF $4.20 - $4.30. THIS INCLUDES A BENEFIT OF APPROXIMATELY 10 CENTS FROM RECENTLY PASSED LEGISLATION THAT ALLOWS U.S. BASED R&D SPEND TO BE TAX-DEDUCTIBLE IN THE QUARTER, REPURCHASED APPROXIMATELY 4.5 MILLION SHARES OF ILLUMINA STOCK FOR $380 MILLION AT AN AVERAGE PRICE OF $84.66 PER SHARE ENTERED INTO A DEFINITIVE AGREEMENT TO ACQUIRE SOMALOGIC FROM STANDARD BIOTOOLS; TRANSACTION EXPECTED TO CLOSE IN THE FIRST HALF OF 2026, SUBJECT TO REGULATORY APPROVAL SAN DIEGO , JULY 31, 2025 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ: ILMN) ("ILLUMINA" OR THE "COMPANY") TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL YEAR 2025.

ILLUMINA REPORTS FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL YEAR 2025

ILLUMINA TRUSIGHT ONCOLOGY 500 V2 RESEARCH ASSAY IS NOW AVAILABLE WITH BUILT-IN HRD BIOMARKER DETECTION, FASTER TURNAROUND TIME, AND LOWER TISSUE SAMPLE INPUT ILLUMINA'S GROWING RESEARCH AND CLINICAL ONCOLOGY PORTFOLIO BROADENS ACCESS TO CRITICAL BIOMARKER TESTING SAN DIEGO , JULY 30, 2025 /PRNEWSWIRE/ -- ILLUMINA INC. (NASDAQ: ILMN) TODAY ANNOUNCED THE LAUNCH OF THE NEXT GENERATION OF TRUSIGHT ONCOLOGY 500, ITS FLAGSHIP CANCER RESEARCH ASSAY THAT ENABLES COMPREHENSIVE GENOMIC PROFILING. COMPREHENSIVE GENOMIC PROFILING (CGP) IS A CRITICAL TOOL TO ACCELERATE ACCESS TO PRECISION MEDICINE BY PROVIDING A MOLECULAR TUMOR PROFILE TO LABS ADVANCING RESEARCH IN THERAPY SELECTION AND CLINICAL TRIAL ELIGIBILITY.

ILLUMINA ENHANCES FLAGSHIP ASSAY TO ACCELERATE ACCESS TO COMPREHENSIVE TUMOR PROFILING

SAN DIEGO , JULY 10, 2025 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ: ILMN) ANNOUNCED TODAY THAT IT WILL ISSUE RESULTS FOR THE SECOND QUARTER 2025 FOLLOWING THE CLOSE OF MARKET ON THURSDAY, JULY 31, 2025. ON THE SAME DAY, AT 1:30 PM PACIFIC TIME (4:30 PM EASTERN TIME) JACOBTHAYSEN, PHD, CHIEF EXECUTIVE OFFICER, AND ANKUR DHINGRA, CHIEF FINANCIAL OFFICER, WILL HOST A CONFERENCE CALL WITH ANALYSTS, INVESTORS, AND OTHER INTERESTED PARTIES TO DISCUSS FINANCIAL AND OPERATING RESULTS.

ILLUMINA TO ANNOUNCE SECOND QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, JULY 31, 2025

ILLUMINA WAS ALSO RECOGNIZED AS ONE OF THE BEST COMPANIES TO WORK FOR BYU.S. NEWS & WORLD REPORT SAN DIEGO , JULY 10, 2025 /PRNEWSWIRE/ -- ILLUMINA INC. (NASDAQ: ILMN) TODAY ANNOUNCED TWO AWARDS RECOGNIZING THE COMPANY'S LEADERSHIP IN SUSTAINABILITY PRACTICES AND AS AN EMPLOYER OF CHOICE. TIME NAMED ILLUMINA TO ITS WORLD'S MOST SUSTAINABLE COMPANIES LIST FOR THE SECOND YEAR IN A ROW, AND U.S. NEWS & WORLD REPORT NAMED ILLUMINA TO ITS BEST COMPANIES TO WORK FOR LIST.

ILLUMINA NAMED TO TIME'S WORLD'S MOST SUSTAINABLE COMPANIES LIST FOR THE SECOND CONSECUTIVE YEAR

COMBINES HIGHLY COMPLEMENTARY PROTEOMICS EXPERTISE WITH ILLUMINA'S INDUSTRY-LEADING PRODUCT INNOVATION AND GLOBAL MARKET REACH POSITIONS ILLUMINA TO ACHIEVE GROWTH IN A LARGE, EXPANDING MARKET ILLUMINA AND SOMALOGIC HAVE PARTNERED IN PROTEOMICS CO-DEVELOPMENT SINCE LATE 2021 SAN DIEGO , JUNE 23, 2025 /PRNEWSWIRE/ -- ILLUMINA, INC. (NASDAQ: ILMN) ANNOUNCED TODAY IT HAS ENTERED INTO A DEFINITIVE AGREEMENT WITH STANDARD BIOTOOLS (NASDAQ: LAB) UNDER WHICH ILLUMINA WILL ACQUIRE SOMALOGIC, A LEADER IN DATA-DRIVEN PROTEOMICS TECHNOLOGY, AND OTHER SPECIFIED ASSETS FOR $350 MILLION IN CASH PAYABLE AT CLOSING, SUBJECT TO CUSTOMARY ADJUSTMENTS, PLUS UP TO $75 MILLION IN NEAR-TERM PERFORMANCE-BASED MILESTONES ANDPERFORMANCE-BASED ROYALTIES. "THE ACQUISITION OF SOMALOGIC WILL ENHANCE ILLUMINA'S PRESENCE IN THE EXPANDING PROTEOMICS MARKET AND ADVANCE THE MULTIOMICS STRATEGY WE ANNOUNCED IN 2024.

ILLUMINA TO ACQUIRE SOMALOGIC, ACCELERATING ITS PROTEOMICS BUSINESS AND ADVANCING THE COMPANY'S MULTIOMICS STRATEGY

BALTIMORE--(BUSINESS WIRE)--INFINITY BIO, A BIOTECHNOLOGY COMPANY PIONEERING TECHNOLOGIES TO MAP IMMUNE RESPONSES AT SCALE, TODAY ANNOUNCED THE SUCCESSFUL CLOSING OF AN $8 MILLION SERIES A FINANCING ROUND. THE ROUND WAS LED BY ILLUMINA VENTURES, WITH PARTICIPATION FROM PTX CAPITAL, BLACKBIRD BIOVENTURES, AND PROPEL BALTIMORE FUND. AS PART OF THE STRATEGIC PLAN TO BROADEN ITS SUITE OF SERVICE OFFERINGS, INFINITY BIO HAS ACQUIRED THE ASSETS OF SERIMMUNE, INC., WHICH WAS FOUNDED IN 2014 TO PROVIDE.

INFINITY BIO CLOSES $8M SERIES A FINANCING LED BY ILLUMINA VENTURES TO EXPAND LEADERSHIP IN ANTIBODY REACTOME PROFILING

SAN DIEGO , JUNE 10, 2025 /PRNEWSWIRE/ -- ILLUMINA INC. (NASDAQ: ILMN), ALIGNED WITH ITS COMMITMENTS TO ADVANCE THE POWER OF GENOMICS, TODAY PUBLISHED ITS ANNUAL CORPORATE SOCIAL RESPONSIBILITY (CSR) REPORT. THE REPORT SPOTLIGHTS THE WAYS ILLUMINA IS MAKING PRECISION HEALTH MORE ACCESSIBLE THAN EVER BEFORE, AND ITS ONGOING WORK TO EMPOWER PEOPLE AND COMMUNITIES, EMBED SUSTAINABILITY ACROSS ITS BUSINESS, OPERATE RESPONSIBLY, AND LEAD WITH INTEGRITY.

LLLUMINA RELEASES 2024 CORPORATE SOCIAL RESPONSIBILITY REPORT AS IT ADVANCES ITS VISION TO UNLOCK THE POWER OF GENOMICS

NEW AI ALGORITHM ACCURATELY DECIPHERS PATHOGENIC REGULATORY GENETIC VARIANTS IN THE NONCODING REGIONS OF THE HUMAN GENOME AT SCALE FOR THE FIRST TIME SAN DIEGO , MAY 29, 2025 /PRNEWSWIRE/ -- ILLUMINA INC. (NASDAQ: ILMN) TODAY UNVEILED PROMOTERAI, A NEW AI ALGORITHM THAT ACCURATELY DECIPHERS PATHOGENIC REGULATORY GENETIC VARIANTS IN THE NONCODING REGIONS OF THE HUMAN GENOME. A STUDY PUBLISHED TODAY IN SCIENCE ILLUSTRATES HOW THIS DEEP LEARNING TECHNOLOGY DISCOVERED REGULATORY VARIANTS IN NONCODING "PROMOTER" SEGMENTS THAT CONTRIBUTE UP TO 6% OF THE GENETIC CAUSES OF RARE DISEASES.

ILLUMINA UNVEILS PROMOTERAI, A GROUNDBREAKING ALGORITHM TO ACCELERATE INSIGHTS FOR RARE DISEASE DIAGNOSIS

FOLLOWING FDA APPROVAL LAST YEAR, ILLUMINA'S TSO COMPREHENSIVE TEST GAINS BROAD PAYER REIMBURSEMENT, EXPANDING ACCESS TO COMPREHENSIVE GENOMIC PROFILING TO MATCH PATIENTS WITH TARGETED THERAPIES ILLUMINA'S IVD PORTFOLIO WILL ALSO EXPAND TO OFFER PILLAR ONCOREVEALCDX, THE NEWEST PANEL TO DELIVER CRITICAL COMPANION DIAGNOSTIC TESTING USING THE ILLUMINA MISEQ DX SYSTEM SAN DIEGO , MAY 28, 2025 /PRNEWSWIRE/ --ILLUMINA INC. (NASDAQ: ILMN) TODAY ANNOUNCED AN EXPANDED CLINICAL ONCOLOGY PORTFOLIO, UNLOCKING THE NEXT NEW SOLUTIONS TO ADVANCE PRECISION ONCOLOGY AND IMPROVE THE STANDARD OF CARE. THE COMPANY'S BROAD RANGE OF CLINICAL OFFERINGS WILL ACCELERATE ACCESS TO PRECISION ONCOLOGY FOR MORE PATIENTS WITH CANCER.

ILLUMINA EXPANDS CLINICAL ONCOLOGY PORTFOLIO UNLOCKING NEW STANDARD OF CARE AND ACCESS TO PRECISION THERAPIES

FOSTER CITY, CALIF.--(BUSINESS WIRE)--SIGNIOS BIOSCIENCES (SIGNIOS BIO), A SCIENCE-FIRST BIOTECHNOLOGY COMPANY LEADING IN MULTIOMICS AND AI-POWERED BIOINFORMATICS, IN COLLABORATION WITH ILLUMINA, ANNOUNCED TODAY AN ILLUMINA-SPONSORED GRANT FOR EARLY ACCESS TO ILLUMINA PROTEIN PREP 9.5K. POWERED BY SOMAMER TECHNOLOGY, THIS NEXT-GENERATION SEQUENCING (NGS)-BASED PLATFORM ENABLES COMPREHENSIVE PROTEOMIC PROFILING OF PLASMA AND SERUM. ILLUMINA PROTEIN PREP 9.5K UTILIZES SLOW OFF-RATE MODIFIED.

Illumina, Inc.

ILMN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Illumina, Inc.

ILMN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ILMN